Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
European Urology|November 9, 2010
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised diseaseAxel Heidenreich, Joaquim Bellmunt, Michel Bolla, et al.
European Urology|February 15, 2011
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancerNicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al.
European Urology|November 12, 2013
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013Axel Heidenreich, Patrick J Bastian, Joaquim Bellmunt, et al.
European Urology|December 5, 2006
A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinomaHendrik Van Poppel, Luigi Da Pozzo, Walter Albrecht, et al.
European Urology|December 28, 2010
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinomaHendrik Van Poppel, Luigi Da Pozzo, Walter Albrecht, et al.
European Urology|November 2, 2015
Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)Claude Schulman, Erik Cornel, Vsevolod Matveev, et al.
Targeted Oncology|June 6, 2020
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer RegistrySimon Chowdhury, Anders Bjartell, Nicolaas Lumen, et al.
Targeted Oncology|April 7, 2021
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer RegistryAnders Bjartell, Nicolaas Lumen, Pablo Maroto, et al.
The Lancet. Oncology|October 17, 2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trialTomasz M Beer, Sebastien J Hotte, Fred Saad, et al.
Asian Journal of Urology|December 22, 2017
A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and RussiaDingwei Ye, Yiran Huang, Fangjian Zhou, et al.
Pageof 5